SRNE - Sorrento Therapeutics' Multifaceted Plan to Attack COVID-19
Sorrento Therapeutics (NASDAQ: SRNE) arguably has the most diverse set of products for the COVID-19 pandemic. In this video from Motley Fool Live recorded on Nov. 12, executives from the company talk about a few of the biotech's preclinical products. Salicyn 30 is an antiviral that blocks infection of cells by the novel coronavirus. COVIDTRAP is an ACE2 receptor decoy, which could bind up the coronavirus and keep it from infecting cells. And STI 8282 is a stem cell product designed to help patients recover from lung damage.
For further details see:
Sorrento Therapeutics' Multifaceted Plan to Attack COVID-19